amlodipine + valsartan + hydrochlorothiazide (HK inno.N Corporation)

Exone Plus is an oral fixed-dose triple combination therapy developed by HK inno.N (formerly CJ Healthcare) for the treatment of essential hypertension. It combines three antihypertensive agents with complementary mechanisms of action: amlodipine (a dihydropyridine calcium channel blocker), valsartan (an angiotensin II receptor blocker), and hydrochlorothiazide (a thiazide diuretic). Amlodipine reduces peripheral vascular resistance by inhibiting the influx of calcium ions into vascular smooth muscle; valsartan selectively blocks the binding of angiotensin II to the AT1 receptor, inhibiting its vasoconstrictive and aldosterone-secreting effects; and hydrochlorothiazide promotes diuresis and reduces blood volume by inhibiting sodium reabsorption in the distal convoluted tubule of the kidney. This combination is typically indicated for patients whose blood pressure is not adequately controlled by dual therapy.

Brand names

Exone Plus엑스원플러스엑스원플러스정